Keyword: Mavyret (glecaprevir and pibrentasvir)
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.
The FDA is tracking rare cases of liver damage and even death, mostly in patients who shouldn't have been taking the drugs in the first place.
Gilead Sciences launches its first campaign for hepatitis C treatment Epclusa, highlighting its versatility across different strains of the disease.
Joining the list of top 10 pharma TV spenders were a group of new brands including Aimovig, Mavyret and Truvada.
AbbVie is pushing its time-to-cure advantage in new ads for hepatitis C treatment Mavyret that emphasize a cure “in only 8 weeks.”
New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.
AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.
AbbVie CFO Bill Chase will retire in 2019 after helming finance since the company's birth in 2013. He'll be replaced by controller Robert Michael.
